insights_auto
GNLX の上昇理由: 2.40%?
さらに詳しくchevron_right
GNLX:NASDAQ
Genelux Corp
$2.56
arrow_upward
+2.40%(+0.060) 1 日
10月9日, 16:00:01 GMT-4 · USD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoGNLX の上位の分析情報を生成しています...
始値
$2.48
高値
$2.57
安値
$2.47
時価総額
1.16億
平均出来高
27.54万
取引量
15.46万
52 週高値
$8.54
52 週安値
$2.29
EPS
-$0.87
ベータ版
0.59
発行済株式数
4524.50万
従業員数
26
始値
$2.48
高値
$2.57
安値
$2.47
時価総額
1.16億
平均出来高
27.54万
取引量
15.46万
52 週高値
$8.54
52 週安値
$2.29
EPS
-$0.87
ベータ版
0.59
発行済株式数
4524.50万
従業員数
26
ニュース記事
情報源: ウェブソース、ニュース パートナー
https://www.dars.gov.et/
·
1 週間前
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Momentum Surge Alerts
プロフィール
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Genelux Corp について